Paradigm Completes Phase 3 Enrolment as Zilosul Trial Moves Toward Interim Analysis

RecovryAI Completes Patient Phase of Pivotal Trial Evaluating Its Clinical AI in Advance of FDA De Novo Filing

DANVILLE, Calif.--(BUSINESS WIRE)--Jul 30, 2026-

Paradigm completes Phase 3 enrolment as Zilosul trial moves toward interim analysis

Paradigm Biopharmaceuticals (ASX:PAR) has completed enrolment in its pivotal global Phase 3 trial for Zilosul, marking a major milestone as the company shifts its focus toward patient follow-up, interim analysis and the delivery of key clinical data. Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more. A total of 538 participants have commenced t…